Advertisement

Advertisement

Breast Cancer

Have Breast Cancer Mortality Rates Stopped Declining for Younger Women?

Breast cancer death rates have stopped declining for women in the United States younger than age 40, ending a trend that existed from 1987 to 2010, according to a report published by Hendrick et al in Radiology. Breast cancer is the most common nonskin cancer and the second most common cause of...

Breast Cancer

Elacestrant for Heavily Pretreated Patients With ER-Positive, HER2-Negative Metastatic Breast Cancer

In a phase I trial reported in the Journal of Clinical Oncology, Aditya Bardia, MD, MPH, and colleagues identified activity of the oral selective estrogen receptor (ER) degrader (SERD) elacestrant in postmenopausal women with heavily pretreated ER-positive, HER2-negative breast cancer, including...

Breast Cancer
Supportive Care
Survivorship

Expert Point of View: Shoshana Rosenberg, ScD, MPH

Shoshana Rosenberg, ScD, MPH, Assistant Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, Boston, weighed in on the implications of these findings. “The study underscores the importance of addressing psychosocial health in survivorship. it targeted a particularly...

Breast Cancer
Supportive Care
Survivorship

Meditation and Education Interventions May Improve Depressive Symptoms in Young Breast Cancer Survivors

A diagnosis of breast cancer and subsequent treatment may increase the risk of depression, especially among younger women with breast cancer. A new study showed that behavioral interventions—specifically mindfulness meditation and survivorship education classes—may reduce depressive symptoms, as...

Breast Cancer
Immunotherapy

Expert Point of View: William Gradishar, MD

William Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine and Deputy Director for the Clinical Network of the Lurie Cancer Center, commented on the findings of the ASCENT biomarker analysis in the closing panel discussion. The...

Breast Cancer
Immunotherapy

Is Trop-2 Expression Associated With Benefit From Sacituzumab Govitecan-hziy?

The antibody-drug conjugate sacituzumab govitecan-hziy (sacituzumab govitecan) is beneficial in previously treated patients with metastatic triple-negative breast cancer, irrespective of Trop-2 expression, according to a biomarker analysis of the phase III ASCENT trial.1 Although greater efficacy...

Breast Cancer
Survivorship

Study Examines Pregnancy Outcomes in Breast Cancer Survivors

Breast cancer survivors of child-bearing age appear to have a more difficult time becoming pregnant than the general population, and when they do become pregnant, they have a higher risk of preterm labor and need for cesarean section. Fortunately, most women deliver healthy babies, but they are...

Breast Cancer

Expert Point of View: Neil M. Iyengar, MD

Neil M. Iyengar, MD, Assistant Attending Physician at Memorial Sloan Kettering Cancer Center, New York, has researched the links between breast cancer and lifestyle. He provided comments on these two abstracts from the 2020 San Antonio Breast Cancer Symposium (SABCS) for The ASCO Post. “These two...

Breast Cancer

Can a High-Carbohydrate Diet Increase the Risk for Breast Cancer?

A growing body of evidence is showing a strong association between diet and breast cancer risk and survival, particularly high glycemic load and sugar intake. Two large population studies at the 2020 San Antonio Breast Cancer Symposium supported these observations.1,2 Findings from the Nurses’...

Breast Cancer
Issues in Oncology

Role of Twitter in Identifying Barriers to Care Among Patients With Metastatic Breast Cancer

Information shared by women with metastatic breast cancer on social media platforms like Twitter may be a timely source of data for policymakers hoping to improve care and outcomes for these patients, according to a study published by Shimkhada et al in JMIR Public Health and Surveillance. Role of...

Breast Cancer

Breast Cancer–Specific Mortality by Race/Ethnicity and 21-Gene Recurrence Scores

In a U.S. population–based cohort study reported in JAMA Oncology, Hoskins et al found that among patients with estrogen receptor–positive breast cancer, Black women were more likely than White women to have a high Oncotype DX 21-gene recurrence score. Researchers also found that breast...

Issues in Oncology
COVID-19
Breast Cancer
Lung Cancer
Gynecologic Cancers
Global Cancer Care

Impact of COVID-19 on Cancer Care Has Been ‘Profound,’ According to WHO

More than a year since the new coronavirus crisis began, its impact on cancer care has been stark, with “50% of governments (having) cancer services partially or completely disrupted because of the pandemic,” said André Ilbawi, MD, of the World Health Organization’s (WHO) Department of...

Breast Cancer
Immunotherapy

Margetuximab-cmkb vs Trastuzumab in Heavily Pretreated Patients With HER2-Positive Breast Cancer: SOPHIA Trial

As reported in JAMA Oncology by Hope S. Rugo, MD, and colleagues, the phase III SOPHIA trial has shown significantly prolonged progression-free survival with margetuximab-cmkb plus chemotherapy vs trastuzumab plus chemotherapy in patients with HER2-positive breast cancer who experienced disease...

Breast Cancer
Genomics/Genetics

Protein-Truncating and Rare Missense Variants in Breast Cancer Risk Genes: Association With Disease Risk

In a study reported in The New England Journal of Medicine, members of the international Breast Cancer Association Consortium (BCAC) identified the risk of disease associated with germline protein-truncating and rare missense variants of putative susceptibility genes in a large population of breast ...

Breast Cancer
Symptom Management
Issues in Oncology

Expert Point of View: Virginia Kaklamani, MD

Press conference moderator Virginia Kaklamani, MD, of UT Health San Antonio, and Leader of the Breast Cancer Program, UT Health San Antonio MD Anderson Cancer Center, weighed in on this study. “This study compared patients’ reports with physicians’ reports about the severity of symptoms. It is a...

Breast Cancer
Symptom Management
Issues in Oncology

Severity of Patients’ Symptoms May Be Underrecognized During and After Breast Radiotherapy

Physicians may commonly underrecognize radiation-associated symptoms and their severity compared with self-reports of patients with breast cancer, according to a large study comparing patient-­reported outcomes with physician assessments of four common radiation-associated symptoms: pain, pruritus, ...

Breast Cancer
Geriatric Oncology

New Surveillance Mammography Screening Guidelines Issued for Breast Cancer Survivors Aged 75 and Older

A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on screening in survivors’ later years. The guidelines, published today by Rachel A. Freedman, MD, MPH, and ...

Breast Cancer

Addition of Adjuvant Palbociclib to Ongoing Endocrine Therapy in HR-Positive, HER2-Negative Early Breast Cancer: PALLAS Trial

As reported in The Lancet Oncology by Erica L. Mayer, MD, and colleagues, the second interim analysis of the phase III PALLAS trial showed no improvement in invasive disease–free survival with the addition of adjuvant palbociclib to ongoing endocrine therapy in patients with hormone receptor...

Breast Cancer
Genomics/Genetics

Prevalence of and Risk Associated With Breast Cancer Predisposition Genes: U.S. Population-Based Study

In a U.S. population-based, case-control study reported in The New England Journal of Medicine, Hu et al identified the prevalence of and risk associated with germline pathogenic variants in established and candidate breast cancer predisposition genes. Study Details The study involved 32,247 women...

Breast Cancer

Finding Hope With Cancer

Sometimes there just is no escaping cancer. I thought I had done everything right. I was diligent about adhering to my annual physical exams, including mammograms, and routinely performed breast self-exams to spot any early changes in my breasts. Still, in the summer of 2015, I was diagnosed with...

Breast Cancer

Significant Survival Benefit From Chemotherapy for Older Women With Triple-Negative Breast Cancer

Women older than age 70 diagnosed with triple-negative breast cancer had significantly improved overall survival if they received adjuvant and/or neoadjuvant chemotherapy, according to an analysis of data from more than 16,000 women enrolled in the National Cancer Database. The estimated 5-year...

Breast Cancer

Chemotherapy Added to Local Therapy Improves Overall Survival in Older Women With Triple-Negative Breast Cancer

In a National Cancer Database analysis reported in The Lancet Oncology, Jennifer A. Crozier, MD, of the Division of Cancer Medicine, Baptist MD Anderson Cancer Center, Jacksonville, and colleagues found that receipt of neoadjuvant or adjuvant chemotherapy was associated with improved overall...

Breast Cancer

Expert Point of View: C. Kent Osborne, MD, and Ruth M. O’Regan, MD

Commentary for monarchE and PENELOPE-B was provided by C. Kent Osborne, MD, and Ruth M. O’Regan, MD, respectively. Dr. Osborne is Professor of Medicine, Hematology, and Oncology and the Dudley and Tina Sharp Chair for Cancer Research at Baylor College of Medicine, as well as Founding Director of...

Breast Cancer

A Tale of Two CDK4/6 Inhibitors in Early Breast Cancer

The primary outcome analysis of the phase III monarchE trial, an update of previous data, continued to show significant benefit for abemaciclib in the adjuvant setting, reducing the risk for invasive disease recurrence by 28.7%. Meanwhile, the first results of the phase III PENELOPE-B trial of...

Breast Cancer

Ipatasertib Plus Paclitaxel Falters in Advanced Triple-Negative Breast Cancer Phase III Trial

The combination of ipatasertib plus paclitaxel failed to improve progression-free survival in PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer, according to results from cohort A of the phase III IPATunity130 trial, presented at the 2020 San...

Breast Cancer

Expert Point of View: Yuan Yuan, MD, PhD

Yuan Yuan, MD, PhD, a medical oncologist at City of Hope, Duarte, California, said that this was yet another failed phase III trial following promising phase II data. “Entinostat was granted Fast Track designation by the U.S. Food and Drug Administration several years back based on preclinical and...

Breast Cancer

Adding Entinostat to Exemestane Fails to Overcome Aromatase Inhibitor Resistance in Advanced Breast Cancer

The histone deacetylase inhibitor (HDAC) entinostat, added to exemestane, failed to overcome endocrine therapy resistance in advanced breast cancer, according to the E2112 phase III trial conducted by the ECOG-ACRIN Cancer Research Group. Results showed that overall survival was not improved by the ...

Breast Cancer

Expert Point of View: Hatem Soliman, MD

“The updated long-term follow-up from IBIS II showed that tamoxifen and anastrozole have similar efficacy in preventing breast cancer recurrences in patients diagnosed with ductal carcinoma in situ. However, there were differences in side effects consistent with the known safety profiles of these...

Breast Cancer

KEYNOTE-355: Pembrolizumab Plus Chemotherapy Improves Progression-Free Survival in PD-L1–Enriched Advanced Triple-Negative Breast Cancer

Pembrolizumab plus chemotherapy improved progression-free survival vs chemotherapy alone as first-line treatment of advanced or metastatic triple-negative breast cancer, according to the results of KEYNOTE-355.1 Progression-free survival was significantly improved with pembrolizumab plus...

Breast Cancer

Anastrozole vs Tamoxifen to Prevent DCIS Recurrence: Key Difference May Be Side-Effect Profile

If your patient were an older woman opting for hormonal therapy after surgically excised ductal carcinoma in situ (DCIS), which hormonal agent would you recommend for the prevention of disease recurrence: tamoxifen or anastrozole? According to long-term follow-up of the large, randomized IBIS...

Breast Cancer

Expert Point of View: William Gradishar, MD

Thoughts on oral taxanes—and in particular, tesetaxel—were provided by William Gradishar, MD, the Betsy Bramsen Professor of Breast Oncology at Northwestern University Feinberg School of Medicine and Deputy Director for the Clinical Network of the Lurie Cancer Center. Dr. Gradishar commented that...

Breast Cancer

Oral Taxanes Moving Forward in Metastatic Breast Cancer

Positive results have now been reported in phase III trials of two oral taxanes in the treatment of metastatic breast cancer. At the 2020 San Antonio Breast Cancer Symposium, treatment with tesetaxel and reduced-dose capecitabine resulted in an improvement in progression-free survival of about 3...

Breast Cancer

Expert Point of View: Cristina Saura Manich, MD, PhD

Study discussant Cristina Saura Manich, MD, PhD, Head of the Breast Cancer Program at the Vall d’Hebron University Hospital in Barcelona, offered some thoughts as to the underlying mechanism of benefit from trilaciclib in the phase II study reported by Dr. Joyce A. O’Shaugnessy. Trilaciclib is a...

Breast Cancer

Unexpected Survival Benefit Reported With Trilaciclib in Metastatic Triple-Negative Breast Cancer

The intravenous administration of trilaciclib, the first-in-class reversible inhibitor of cyclin-dependent kinase 4/6 (CDK4/6), given with chemotherapy, led to a significant improvement in overall survival in previously treated patients with metastatic triple-negative breast cancer, compared with...

Breast Cancer

Margetuximab-cmkb for Previously Treated Metastatic HER2-Positive Breast Cancer

On December 16, 2020, margetuximab-cmkb (margetuximab) was approved for use in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.1,2...

Breast Cancer

New Study Finds Suspicious Lesions on Breast MRI in Neoadjuvant Setting Are Unlikely to Be Malignant

According a new study published by Eckstein et al in the American Journal of Roentgenology (AJR), new suspicious findings occurred in 5.5% of breast magnetic resonance imaging (MRI) examinations performed to monitor patients’ response to neoadjuvant therapy; none of these newly detected lesions...

Breast Cancer
Legislation
Issues in Oncology

Dense Breast Notification Legislation: Recorded Effects and Future Recommendations

According to findings published by Kressin et al in the Journal of the American College of Radiology, women living in states where dense breast notifications are legislatively mandated had higher rates of being informed about personal breast density and of having had breast density discussions with ...

Breast Cancer
Geriatric Oncology
Symptom Management

Novel Risk Tool for Predicting Severe Toxicity in Older Patients Receiving Chemotherapy for Early-Stage Breast Cancer

As reported in the Journal of Clinical Oncology, Allison Magnuson, DO, and colleagues have developed a risk tool for predicting severe toxicity in patients aged 65 and older receiving chemotherapy for early-stage breast cancer. Study Details The prospective cohort study included 473 patients...

Breast Cancer
Issues in Oncology

Performing Mammograms for Targeted Hospitalized Patients

Completing cancer screening tests such as mammograms can be challenging for low-income patients who may face such issues as lack of transportation or inability to take time off work. A team at Massachusetts General Hospital explored the possibility of addressing preventive care needs when patients...

COVID-19
Breast Cancer
Survivorship

Italian Study of Electronic Medical Record–Assisted Telephone Follow-up of Breast Cancer Survivors During the COVID-19 Pandemic

In an Italian single-institution study reported in JCO Oncology Practice, Merz et al evaluated the use of electronic medical record–assisted telephone follow-up (E-TFU) of breast cancer survivors to minimize hospital exposure over a 3-month period during the COVID-19 pandemic. The strategy was...

Breast Cancer

Palbociclib Plus Endocrine Therapy vs Capecitabine for Patients With HR-Positive, HER2-Negative Breast Cancer: The PEARL Trial

Although patients with hormone receptor (HR)-positive, HER2-negative, aromatase inhibitor–resistant metastatic breast cancer maintained quality of life for a longer time following treatment with palbociclib plus either exemestane or fulvestrant than capecitabine, those receiving chemotherapy...

Breast Cancer

Can Postoperative Whole-Breast Irradiation Be Safely Omitted in Older Women With Low-Risk Breast Cancer?

Omitting postoperative radiotherapy with whole-breast irradiation may not compromise 10-year overall survival or increase the risk of developing metastasis in most women 65 years and older with low-risk breast cancer, according to results of the large randomized PRIME II trial reported at the 2020...

Breast Cancer
Gynecologic Cancers
Colorectal Cancer

Rates of Eligible People Missing Timely Cancer Screenings: A Canadian Analysis

New research published by Abdel-Rahman in JNCCN—Journal of the National Comprehensive Cancer Network found more than one-third of eligible people miss timely screening tests for colorectal cancer, and at least one-quarter appear to miss timely screening tests for breast and cervical cancers....

Breast Cancer
Pain Management

New Study Examines Patterns of Opioid Use Among Patients With Metastatic Breast Cancer

Some patients with metastatic breast cancer are taking smaller doses of opioid prescriptions over decreased amounts of time, according to results published by Shen et al in Scientific Reports. Researchers said that the results indicate that clinicians may be more aware of the negative impacts of...

breast cancer

Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses results from the ALTERNATE trial on response to neoadjuvant chemotherapy in postmenopausal women with clinical stage II or III estrogen receptor–positive and HER2-negative breast cancer that is resistant to endocrine therapy. The findings highlight the need for more effective treatments in this high-risk population (Abstract GS4-05).

breast cancer

Elizabeth A. Mittendorf, MD, PhD, on Her Plenary Lecture: Local Regional Management Following Neoadjuvant Therapy

Elizabeth A. Mittendorf, MD, PhD, of Brigham and Women’s Hospital, summarizes her plenary talk, which featured the uncertainties in treatment knowledge: excision of postchemotherapy calcifications; the best sentinel lymph node biopsy technique for patients with node-positive disease who convert to node-negative disease with neoadjuvant chemotherapy; whether immunohistochemistry should be routinely used for sentinel lymph node evaluation; and the role of radiation therapy in this patient population.

Breast Cancer

Distinct T-Cell Signature in Black Patients With Breast Cancer May Contribute to More Aggressive Disease

A research team has revealed a distinct molecular signature in the tumor tissues of Black patients with breast cancer. The new work, published by Yao et al in JNCI: Journal of the National Cancer Institute, reported that an elevated number of “exhausted,” nonfunctional T cells appears to lead to...

Breast Cancer
Immunotherapy

Subcutaneous Fixed-Dose vs Intravenous Pertuzumab/Trastuzumab for HER2-Positive Early Breast Cancer

As reported in The Lancet Oncology by Tan et al, the phase III FeDeriCa trial showed comparable pharmacokinetics and pathologic complete response rates with a subcutaneous (SC) fixed-dose combination of pertuzumab and trastuzumab vs the same combination administered intravenously (IV)—both given...

Breast Cancer

Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer

Surgery, in addition to treatments like chemotherapy and radiation therapy, may improve survival for certain patients with metastatic breast cancer. A research team studied nearly 13,000 patients with stage IV disease and found that those who had surgery in addition to other treatments had a...

Gynecologic Cancers
Breast Cancer

Study Clarifies Time-Dependent Effects of Oral Contraceptives on Risk of Ovarian, Endometrial, and Breast Cancers

A comprehensive study involving more than 250,000 women showed that oral contraceptive use may be protective against the development of ovarian and endometrial cancers, but the effect on lifetime risk of breast cancer is more limited. The protective effect on ovarian and endometrial cancers was...

Advertisement

Advertisement

Advertisement